Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Immunogenicity and Safety of a Two Vaccination Regimen With an LT Vaccine Patch in Healthy Adults.

Next Previous
Trial Profile

A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Immunogenicity and Safety of a Two Vaccination Regimen With an LT Vaccine Patch in Healthy Adults.

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 31 Jan 2020

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Heat-labile enterotoxin E coli (Primary)
  • Indications Enterotoxigenic Escherichia coli infections; Traveller's diarrhoea
  • Focus Pharmacodynamics
  • Sponsors Intercell USA; Valneva USA

Most Recent Events

  • 11 Dec 2017 According to a Valneva media release, Intercell USA changed its name to Valneva USA.
  • 18 Apr 2014 Primary endpoints and drug dosage have been added as reported by ClinicalTrials.gov record.
  • 12 Aug 2010 Actual end date (November 2009) added as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top